United Cannabis (CNABQ) 10-Q 15 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 14, 2018
Document And Entity Information
Entity Registrant Name	United Cannabis Corp
Entity Central Index Key	1,436,161
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		64,229,926
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,018

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 164,961	$ 825,645
Accounts receivable, net	34,513
Inventory	137,141	43,200
Due from related parties	14,961
Other current assets	18,216	23,028
Total current assets	369,792	891,873
Construction in progress	110,699	832,697
Cultivation facility, laboratory equipment and office furniture and fixtures, and leasehold improvements net of accumulated amortization and depreciation of $91,524 and $39,385 at March 31, 2018 and December 31, 2017, respectively	1,333,065	199,821
Granted patents, net of accumulated amortization of $4,458 and $2,679 for March 31, 2018, and December 31, 2017, respectively	137,859	139,638
Intangible assets	220,962	170,519
Goodwill	4,838,603	4,838,603
Total assets	7,010,980	7,073,151
Current liabilities:
Accounts payable	177,021	371,711
Accrued expenses	9,209	10,184
Installment loan payable	32,757	46,667
Current portion of deferred revenue	158,750	180,000
Accrued wages payable to officers, directors and employees	201,664	310,401
Notes payable to and advances from officers and directors	341,544	261,348
Total current liabilities	920,945	1,180,311
Long term liabilities:
Deferred revenue, net of current portion		23,750
Total liabilities	920,945	1,204,061
COMMITMENTS AND CONTINGENCIES - Note 19
STOCKHOLDERS' EQUITY
Preferred stock, 10,000,000 shares authorized; 2,000 Series A shares outstanding at March 31, 2018 and December 31, 2017, respectively	2,200	2,200
Common stock, 100,000,000 shares authorized; 64,229,926 and 62,862,066 outstanding as of March 31, 2018 and December 31, 2017, respectively	28,669,844	21,186,888
Accumulated deficit	(22,476,406)	(15,269,845)
Total equity (deficit) attributable to stockholders of the Company	6,195,638	5,919,243
Non-controlling interest (deficit)	(105,603)	(50,153)
Total stockholders' equity	6,090,035	5,869,090
Total liabilities and stockholders' equity	$ 7,010,980	$ 7,073,151

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Accumulated depreciation	$ 91,524	$ 39,385
Accumulated amortization	$ 4,458	$ 2,679
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares outstanding	64,229,926	62,862,066
Series A Preferred Stock [Member]
Preferred stock, shares issued	2,000	2,000
Preferred stock, shares outstanding	2,000	2,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Product sales	$ 164,212	$ 144,677
Licensing fees	45,000	45,000
Licensing fees - affiliate	57,064
Total revenues	266,276	189,677
Cost of revenues:
Cost of revenues	(118,942)	(121,051)
Gross profit	147,334	68,626
Operating expenses:
Marketing, advertising and new business development	17,311	53,392
Research and development	236,678	45,160
Legal, accounting, consulting and public reporting	263,246	240,814
General and administrative	6,327,550	248,860
Total operating expenses	6,844,785	588,226
Loss from operations	(6,697,451)	(519,600)
Other income (expense):
Interest expense	(8,498)	(28,809)
Loss on extinguishment of debt and repurchase of warrants		(267,567)
Loss on settlement of dispute
Loss on issuance of common stock	(556,061)
Loss before taxes on income	(7,262,010)	(815,976)
Provision for taxes on income
Net Loss	(7,262,010)	(815,976)
Loss attributable to non-controlling interests	55,450
Net Loss attributable to common shareholders	$ (7,206,560)	$ (815,976)
Basic and diluted net loss per share:	$ (0.11)	$ (0.02)
Basic and diluted weighted-average common shares outstanding:	63,829,443	50,971,862

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating activities:
Net loss	$ (7,262,010)	$ (815,976)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of debt discount		16,406
Non-cash interest expense		9,694
Depreciation and amortization	53,946	3,239
Share-based compensation	5,488,982	211,967
Loss on issuance of common stock	556,061
Loss on extinguishment of debt and repurchase of warrants		267,559
Increase in net assets in connection with acquisition of fifty percent owned subsidiary		(22,666)
Changes in operating assets and liabilities:
Accounts receivable	(34,513)	(33,150)
Due from related parties	(14,961)
Inventory	(93,941)
Prepaid expenses		5,000
Other current assets	4,811
Accounts payable and accrued expenses	(195,663)	101,564
Deferred revenue	(45,000)	(45,000)
Accrued wages payable to officers, directors and employees	(108,738)	191,563
Net cash used in operating activities	(1,651,026)	(109,800)
Investing activities:
Purchase of equipment for and improvements to cultivation facility	(463,414)	(130,541)
Purchase of intangible assets	(50,443)
Cash in acquisition of fifty percent owned subsidiary		(15,079)
Net cash used in investing activities	(513,857)	(145,620)
Financing activities:
Proceeds from issuance of common stock - equity financing line	1,380,831
Proceeds from advances from officers and directors	80,195	178,383
Proceeds from sale of common stock	57,083
Payments on installment loan	(13,910)
Net cash provided by financing activities	1,504,199	178,383
Net decrease in cash	(660,684)	(77,037)
Cash, beginning of period	825,645	112,621
Cash, end of period	164,961	35,584
Supplemental schedule of cash flow information:
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of non-cash investing and financing activities:
Conversion of convertible note payable to noteholder		125,000
Conversion of advances from officers and directors to notes payable to officers and directors		$ 246,681

BUSINESS ORGANIZATION AND NATUR

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 –BUSINESS ORGANIZATION AND NATURE OF OPERATIONS United Cannabis Corporation ("we", "our", "us", "UCANN", or “the Company”) a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. MySkin was engaged in the business of providing management services to a medical spa in Los Angeles, California which provided various advanced skin care services until March 31, 2014, when this business was sold to the prior President of the Company. In early 2014 we decided to exit the medical spa management business and change our focus to providing products, services and intellectual property to the cannabis industry. On March 26, 2014, we entered into a License Agreement with Earnest Blackmon, Tony Verzura and Chad Ruby pursuant to which Messrs. Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock. In connection with this transaction: · Messrs. Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid therapy program called "A.C.T. Now", security, regulatory compliance, and other methods and processes which relate to the cannabis industry. · The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement. · Messrs. Blackmon, Verzura and Ruby were appointed to our board of directors effective April 7, 2014. · Mr. Blackmon was elected as our President, Mr. Ruby was elected as Chief Operating Officer and Mr. Verzura was elected as Vice President. · A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014. UCANN was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCANN, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation. On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we entered into a new business and no longer had any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA. In addition, MTA assumed all costs associated with these assets starting on March 31, 2014. On July 14, 2017, we completed the acquisition of Prana Therapeutics, Inc. (“Prana”) in a one-for-one exchange of 5,730,000 shares of common stock of the Company for 5,730,000 of common stock of Prana. The purchase price had a fair market value of $5,070,500, based upon the closing price of $0.85 per share on the OTC QB exchange on July 14, 2017, including the cost to purchase 400,000 shares of Prana common stock for $200,000. Prana is a polymolecular botanical drug development company focused on developing targeted therapeutics for prevention of the negative side effects of chemotherapy, management of rheumatoid arthritis and treatment of brain cancer. Management elected to purchase Prana, because of the successful indication of the effectiveness of their Epidiferphane™ chemical formulation in the treatment of (i) the negative side effects of chemotherapy, (ii) inflammation and pain associated with arthritis and back-centric pain, (iii) sleep disorder, and (iv) the potential shrinkage of brain tumors. Government Regulation As of March 31, 2018, 29 states and the District of Columbia allow their citizens to use medical marijuana, and voters in the states of California, Colorado, Washington, Nevada, Oregon, Alaska, Maine, Massachusetts, Vermont and the District of Columbia have approved ballot measures to legalize cannabis for adult recreational use. The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The former Obama administration had effectively stated that it was not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical and recreational marijuana under what colloquially became known as the “Cole memo”. However, on January 4, 2018, Attorney General Jeffery Sessions rescinded the “Cole memo,” and issued a new memo in its place that reaffirms the Department of Justice’s stance of potentially prosecuting violators of federal marijuana laws. On April 13, 2018, President Trump pledged to support federalism-based legislation regarding marijuana and promised not to pursue federal prosecution despite the Attorney General’s actions. It appears that the current administration will not elect to vigorously enforce federal laws, but such future enforcement may cause significant financial damage to us.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation Use of Estimates We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term. Fair Value of Financial Instruments Level 1 Level 2 Level 3 The carrying amount of our cash and cash equivalents, accounts receivable, accounts payable, and other current assets and liabilities in our consolidated financial statements approximates fair value because of the short-term nature of the instruments. Investments in non-marketable equity securities are carried at cost less other-than-temporary impairments. The carrying amount of our notes payable and convertible debt at March 31, 2018, approximates their fair values based on our incremental borrowing rates. There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the three-month period ended March 31, 2018 and the year ended December 31, 2017. Cash and Cash Equivalents Accounts Receivable, Net Prepaid Expenses - Inventory – Property and Equipment March 31, December 31, 2018 2017 Construction in process - extraction facilities Weldona, Colorado extraction facility: Equipment $ — $ 647,947 Jamaica cultivation and extraction facility: Leasehold improvements - laboratory — 75,000 Leasehold improvements - cultivation 110,699 109,750 $ 110,699 $ 832,697 Extraction facility and laboratory equipment, and office furniture and fixtures Equipment and machinery at Weldona extraction facility $ 1,154,909 — Golden, Colorado hemp laboratory - equipment 39,944 34,651 Golden, Colorado administrative offices: Furniture and fixtures 46,849 21,668 Leasehold improvements 2,000 2,000 Transportation equipment 81,667 81,667 Remote laboratory equipment 99,220 99,220 1,424,589 239,206 Accumulated amortization and depreciation (91,524 ) (39,385 ) $ 1,333,065 $ 199,821 Granted Patents – Intangible Assets – Long-Lived Assets Impairment Assessment We have not recorded any impairment charges related to long-lived assets as of March 31, 2018 or December 31, 2017. Equity Method Investments Goodwill Purchase Price Allocation Business Combinations Fair Value Measurements and Disclosures Deferred Revenue Revenue Recognition Revenue from Contracts with Customers over time Revenue for services with a payment in the form of stock, warrants or other financial assets is recognized when the services are performed. The value of revenue paid for with warrants is measured using the Black-Scholes-Merton pricing model. Revenue from product sales, including delivery fees, is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. Reimbursable expenses, including those relating to travel, other out-of-pocket expenses and any third-party costs, are included as a component of revenues. Typically, an equivalent amount of reimbursable expenses is included in cost of revenues. Reimbursable expenses related to time and materials and fixed-fee engagements are recognized as revenue in the period in which the expense is incurred and collectability is reasonably assured. Taxes collected from customers and remitted to governmental authorities are presented in our consolidated statement of operations on a net basis. Revenue Recognition – Affiliate Prana Prana Prana Prana Prana Prana Revenue from Contracts with Customers. Cost of Revenues Research and Development Expenses - General and Administrative Expenses - Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation Income Taxes We follow the provisions of ASC 740, Income Taxes When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations. On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no impact on our income taxes for the year ended year-ended December 31, 2017. Commitments and Contingencies - Certain conditions may exist as of the date our consolidated financial statements are issued, which may result in a loss but which will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. Net Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Three Months Ended March 31, 2018 2017 Warrants to purchase common stock 1,234,027 1,541,112 Stock options, exercisable 11,705,000 3,680,000 Total potentially dilutive securities 12,939,027 5,221,112 Other Comprehensive Income (Loss) Segment Reporting – Concentration of Credit Risk The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Three Months Ended March 31, 2018 2017 Customer A 62% 98% Customer B 21% 2% Customer C 17% —% Percentage of Accounts Receivable: As of March 31, 2018 2017 Customer C 100% 93% Customer D —% 7% Customer E —% —% Recently Issued Accounting Pronouncements In February 2016, the FASB issued guidance on leases which requires entities to recognize right-of-use assets and lease liabilities on the balance sheet for the rights and obligations created by all leases, including operating leases, with terms of more than 12 months. The new guidance also requires additional disclosures on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The new guidance will be effective for us at the beginning of fiscal year 2019. Early adoption is permitted. We are in the process of evaluating the impact the adoption of this guidance will have on our consolidated financial statements and related disclosures. Reclassification -

GOING CONCERN

GOING CONCERN	3 Months Ended
	Mar. 31, 2018
GOING CONCERN [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the three-months ended March 31, 2018, we incurred losses of $7,206,500 and used cash of $1,651,026 in our operating activities. As at March 31, 2018, we had a working capital deficit of $511,153 and an accumulated deficit of $22,476,406. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There is no assurance that these events will be satisfactorily completed.

RECEIVABLE FROM RELATED PARTY

RECEIVABLE FROM RELATED PARTY	3 Months Ended
	Mar. 31, 2018
Receivables [Abstract]
RECEIVABLE FROM RELATED PARTY	NOTE 4 – RECEIVABLE FROM RELATED PARTY In the normal course of business, we make non-interest-bearing advances to Advesa, Inc. (“Advesa’), which is controlled by one of our officers and directors. Such advances are used by Advesa to purchase equipment and to cover the cost of their operations. Additionally, during the year ended December 31, 2017, we purchased certain laboratory equipment from Advesa at an amount equal to their cost of the equipment. Related party amounts due from Advesa were $14,861 and $0.0 at March 31, 2018 and December 31, 2017.

OPERATING LEASES

OPERATING LEASES	3 Months Ended
	Mar. 31, 2018
Leases [Abstract]
OPERATING LEASES	NOTE 5 – OPERATING LEASES Administrative Offices and Hemp Laboratory – Golden, Colorado Effective August 1, 2017, we entered into a triple net lease of approximately 9,882 square feet of commercial space in Golden, Colorado in which our administrative offices and hemp laboratory are located. The term of the lease expires on July 31, 2020 and has no option for renewal. Basic rent is $3,302, $3,500 and $3,800 per month through, July 31, 2018, 2019 and 2020, respectively, plus we are responsible for all utilities. It is our intent presently, to renew the lease annual throughout the term of the lease. Extraction and Cultivation Facility – Weldona, Colorado Effective October 1, 2017, we entered into a triple net lease of approximately 40,000 square feet of industrial space located on five (5) acres of land in Weldona, Colorado that we us as our hemp extraction facility and hemp cultivation center. The term of the lease expires on September 31, 2018, with an annual option to renew the lease on an annual basis, that expires on September 30, 2022. The rent is $7,500 per month throughout the term of the lease, Extraction and Cultivation Facility - Jamaica Our fifty percent (50%) owned subsidiary Cannabinoid Research & Development Company Limited (“CRD”) leases approximately 28 acres of land upon which their cultivation and extraction facility is located near Kingston, Jamaica. The land is leased for $1 per year from the father of one of the directors and members of CRD. Future minimum payments for these leases are: For the twelve Months Ending March 31, 2019 2020 2021 2021 2022 $131,208 $134,398 $105,198 $90,001 $45,001

INVENTORY

INVENTORY	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
INVENTORY	NOTE 6 - INVENTORY Inventory is stated at the lower of cost or net realizable value. Cost is determined based upon the cost to acquire the raw materials, plus internal labor and other costs incurred to produce finished goods inventory. The cost of inventory is principally determined using the last-in first-out method. We periodically review the value of our inventory and provide a write-down of inventory based on our assessment of the market conditions. Any write-down is charged to cost of goods sold. At ended March 31, 2018 and December 31, 2017, our inventory is, as follows: March 31, December 31, 2018 2017 Raw materials $ 38,376 $ 15,000 Work-in-process 57,565 — Finished goods 41,200 28,200 $ 137,141 $ 43,200

PURCHASE OF PRANA THERAPUETICS,

PURCHASE OF PRANA THERAPUETICS, INC.	3 Months Ended
	Mar. 31, 2018
Business Combinations [Abstract]
PUCHASE OF PRANA THERAPUETICS, INC.	NOTE 7 – PURCHASE OF PRANA THERAPUETICS, INC. On June 8, 2017, we entered into an agreement to purchase 400,000 shares of Prana Therapeutics, Inc. (“Prana”), in a private offering of their common shares, for a total consideration of $200,000 (“Subscription Agreement’). In accordance with the terms of the Subscription Agreement, we paid Prana $50,000, upon execution of the Subscription Agreement, and committed to remit $50,000 to Prana on September 30, 2017, December 31, 2017 and March 31, 2018, respectively. Subsequently, on July 14, 2017, we completed the acquisition of Prana in a one-for-one exchange of 5,730,000 shares of our common stock for 5,730,000 shares of common stock of Prana. The purchase price had a fair market value of $5,070,500, based upon the closing price of $0.85 per share of our common stock on the OTC QB exchange on July 14, 2017, including the cost to purchase 400,000 shares of Prana for $200,000. The purchase price for Prana was allocated to the net tangible and intangible assets based upon their fair values as of the acquisition date. The excess of the purchase price over the fair values of the net tangible assets and intangible assets was recorded as goodwill and is generally driven by management’s expectations and ability to realize synergies and achieve strategic growth. The allocation of the purchase price was, as follows: March 31, Patents $ 52,596 Net assets 522,761 Goodwill 4,495,143 Total $ 5,070,500

GRANTED PATENT

GRANTED PATENT	3 Months Ended
	Mar. 31, 2018
Granted Patent [Abstract]
GRANTED PATENT	NOTE 8 – GRANTED PATENT On August 15, 2017, the United States Patent and Trademark Office issued to the Company US Patent #9730911 (the “Patent”) granting exclusive rights to its proprietary composition of matter in liquid formulations, based on compounds extracted from cannabis plant materials; more specifically the composition of matter pertaining to the use of phytocannabinoids, cannabinoids, and specific terpene profiles in liquid form. This composition of matter Patent provides protection for our proprietary formulations. The Patent protects the use of suspending both phytocannabinoids and cannabinoids with specific combinations of cannabis derived terpenes in liquid forms with an array of delivery methods including capsule, sublingual, topical, oral, suppository, and vaporization. Cannabinoids referenced in the application include ratios of tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa), tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), cannabichromenic acid (CBCa), and cannabichromene (CBC). At August 15, 2017, we classified the costs associated with research, legal fees, application costs incurred in the process of being granted the Patent on our consolidated balance sheet in the amount of $142,317, and we began amortizing such cost of the Patent on a straight-line basis over a 15-year period. Amortization expense of the Patent is $4,458 and $0.0 for the three-month period ended March 31, 2018 and 2017, respectively and accumulated amortization is $4,458 and $2,679 at March 31, 2018 and December 31, 2017, respectively.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLES	NOTE 9 – INTANGIBLE ASSETS Our intangible assets are comprised of the costs incurred in pursuing provisional patent applications and applications for design mark and trademarks, which have presently not been approved or issued. The costs associated with our intangible assets are amortized on a straight-line basis over estimated useful lives of 15 years for patents and 10 years for design marks and trademarks once the applications are approved. Costs associated with applications that are not approved will be expensed in the period that the application is rejected or abandoned.

INSTALLMENT LOAN PAYABLE

INSTALLMENT LOAN PAYABLE	3 Months Ended
	Mar. 31, 2018
Installment Loan Payable
INSTALLMENT LOAN PAYABLE	NOTE 10 – INSTALLMENT LOAN PAYABLE Installment loan payable consists of a 48-month installment loan incurred in connection with the purchase of a truck that is used at our extraction facility. The outstanding balance on the installment loan was $32,757 and $46,667 at March 31, 2018, and December 31, 2017, respectively. The terms of the installment loan specify monthly payments of $955, however, we are making payments of $6,955 per month to pay the loan off in a six-month period. As a result of our intentions to pay the loan off in six months, the entire balance of the installment loan has been classified as a current liability.

DEFERRED REVENUE

DEFERRED REVENUE	3 Months Ended
	Mar. 31, 2018
Deferred Revenue Disclosure [Abstract]
DEFERRED REVENUE	NOTE 11 – DEFERRED REVENUE Our deferred revenue consists of: March 31, December 31, 2018 2017 Deferred revenue – WeedMD $ 158,750 $ 203,750 Less – current portion (158,750 ) (180,000 ) Deferred revenue, net of current portion $ — $ 23,750 On June 9, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WMD in exchange for future consulting services and use of our intellectual property. We recorded the $893,750 fair value of these securities as deferred revenue and we recognized $150,000 of this amount as revenue during the period July 1, 2014 through December 31, 2014, based upon our initial three-year estimate of the service period involved. Based on recent discussions with WMD, we now expect to deliver the remaining consulting services and use of our intellectual property to WMD on a relatively consistent monthly basis during the four-year period January 1, 2015 through December 31, 2018. Accordingly, we are now recognizing $15,000 of deferred revenue per month. We recognized $45,000 and $180,000 of revenue applicable to this arrangement in the three months ended March 31, 2018 and the year ended December 31, 2017, respectively. At March 31, 2018, we expect to recognize $158,750 of the remaining $158,750 WMD deferred revenue during the next twelve months and accordingly, we have classified the $158,750 as a current liability on our consolidated balance sheets.

CONVERTIBLE NOTE PAYABLE

CONVERTIBLE NOTE PAYABLE	3 Months Ended
	Mar. 31, 2018
CONVERTIBLE NOTE PAYABLE [Abstract]
CONVERTIBLE NOTE PAYABLE	NOTE 12 – CONVERTIBLE NOTE PAYABLE We do not have any convertible notes payable as of March 31, 2018 and December 31, 2017. On August 10, 2016, we borrowed $125,000 and used the proceeds for working capital purposes. The loan, together with interest at 12% per year, was payable on May 10, 2017. We could prepay the loan at any time. If the loan was repaid on or before October 16, the principal amount which was being repaid would increase by 25%. If the loan was repaid on or before October 16, 2016 through February 12, 2016, the principal amount which was being repaid would increase by 30%. Thereafter, the note could be repaid only upon written consent from the noteholder, and the principal amount that was being repaid would increase by 30%. At any time after the date of the note, the noteholder was entitled to convert all of the outstanding and unpaid principal in to shares of our common stock. Until February 12, 2017, the conversion price was $0.20 per share, and thereafter, the conversion price was at a 45% discount to the lowest closing price of our common stock for the ten trading days preceding the conversion date. The noteholder could not make any conversions that would result in the note holder holding more than 4.99% of our issued and outstanding common stock at any one time. If the note had been held through February 12, 2017, derivative accounting would have applied upon the change to a variable conversion price. This convertible note was paid in full on February 9, 2017.

NOTES PAYABLE TO AND ADVANCES F

NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS	3 Months Ended
	Mar. 31, 2018
NOTES PAYABLE, RELATED PARTIES [Abstract]
NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS	NOTE 13 – NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS Notes payable to and advance from officers and directors consisted of the following: March 31, December 31, 2018 2017 Note payable to Earnie Blackmon, an officer and director $ 332,760 $ 246,458 Note payable to Tony Verzura, an officer and director 15,844 14,889 $ 348,604 $ 261,347 On April 6, 2016, we borrowed $25,000 from Ernest Blackmon and $25,000 from Tony Verzura and used the proceeds to repay principal and interest applicable on our $102,000 convertible promissory note dated October 12, 2015, to JSJ Investments Inc. The loans, together with interest at 12% per year, are payable on December 30, 2016. We may prepay the loans at any time. If the loans are repaid on or before September 30, 2016, the principal amount, which is being repaid, will increase by 10%. If the loans are repaid after September 30, 2016, the principal amount, which is being repaid will increase by 15%. As of December 31, 2016, the loans were not repaid, when they were due, per the terms of the notes, and thus, the principal balance of the notes was increased to $57,500 in the aggregate, with the addition to the principal balance charged to interest expense. During the three months ended March 31, 2018 and the year ended December 31, 2017 Messrs. Blackmon, Verzura and Ruby, who are officers and directors of the Company, paid obligations and expenses on behalf of the Company, from their own individual, personal funds. Such payments have been recorded in the consolidated balance sheets as a component of Notes payable to and advances from officers and directors.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2018
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 14 – STOCKHOLDERS’ EQUITY Preferred Stock On July 18, 2017, the Board of Directors adopted a resolution creating a series of Preferred Shares, no par value per share, designated as the Series A Preferred Shares. We subsequently issued 2,000 shares of our Series A preferred stock for $2,200 to of our officers and directors. Warrants: The following table summarizes our share warrants outstanding as of March 31, 2018 and December 31, 2017: March 31, December 31, 2018 2017 Number of Shares Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price Warrants outstanding, beginning of period 1,209,025 $ 0.21 $ 1,551,356 $ 0.18 Warrants issued to consultants 25,002 132,669 Warrants exercised — (475,000 ) Warrants outstanding, end of period 1,234,027 $ 0.27 1,209,025 $ 0.21 Warrants exercisable, end of period 1,234,027 $ 0.27 1,209,025 $ 0.21 The weighted-average remaining contractual life for warrants outstanding and exercisable at March 31, 2018, is 3.6 years, and the aggregate intrinsic value of warrants outstanding and exercisable at March 31, 2018 is $0. 666,667 warrants issued during the years ended December 31, 2017 were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 % Stock Options On February 28, 2018, we awarded 6,000,000 stock options to various employees under our 2017 Stock Incentive Plan. Of these options, 5,125,000 were fully vested at the time of grant with the remaining 875,000 vesting quarterly through December 31, 2019. The awarded options give the option holder the right to purchase shares of our common stock at $1.08 per share during the ten-year term of the option. We calculated the fair value of each option to be approximately $0.91 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 1.05 Exercise price $ 1.08 Risk free interest rate 2.8 % Expected term (years) 5-10 Expected volatility 197 % Expected dividends 0 % The total grant-date fair value of these options was approximately $6,146,000. Stock-based compensation expense related to these stock options included in general and administrative expenses for the three months ended March 31, 2018 was approximately $5,324,754. The following table summarizes our stock options outstanding as of both March 31, 2018 and December 31, 2017, respectively: Number of Weighted Weighted Stock options outstanding at January 1, 2017 3,680,000 8.9 $ 0.28 Issued 3,957,500 Exercised (1,000,000 ) Expired — Stock options outstanding at December 31, 2017 6,637,500 8.7 $ 0.57 Stock options exercisable at December 31. 2017 6,580,000 8.7 0.57 Stock options outstanding at December 31, 2017 6,637,500 Issued 6,000,000 9.9 1.08 Exercised — Expired — Stock options outstanding at March 31, 2017 12,637,500 9.2 0.78 Stock options exercisable at March 31, 2018 11,705,000 9.2 $ 0.78 The weighted-average remaining contractual life for stock options outstanding and exercisable at March 31, 2018 is 9.2 years, and the aggregate intrinsic value of options outstanding and exercisable at March 31, 2018 is $0.78.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	NOTE 15 – SHARE-BASED COMPENSATION Share-based Compensation We recognize share-based compensation expense in cost of revenues, sales and marketing expenses, research and development expenses, general and administrative expenses, and other income and expenses, based on the fair value of common shares issued for services. In addition, we accrue share-based compensation expense for estimated share-based awards earned during the three months ended March 31, 2018 and 2017, under our 2014 Equity Incentive Plan and our 2017 Equity Incentive Plan. Share-based compensation expense for the three months ended Mach 31, 2018 and 2017 is, as follows: Three Months Ended March 31 2018 2017 Warrants issued for consulting and other services $ — $ 91,333 Common stock issued for accounts payable and accrued expenses — 43,376 Common stock issued for services 65,885 120,616 Common stock issued for advisory board fees 56,043 — Common stock issued as compensation to employees 42,300 — Stock options issued to officers and directors 5,324,754 — $ 5,488,982 $ 255,325 The stock options issued to officers and directors were issued under the 2018 Stock Incentive Plan, and such shares were fully vested at the date of grant.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 16 – COMMITMENTS AND CONTINGENCIES Contractual Obligations and Commercial Commitments Financing Commitment On January 19, 2018, we entered into an equity line of credit agreement with Tangiers Global, LLC (“Tangiers”). Under the equity line agreement, Tangiers has agreed to provide the Company with up to $10,000,000 of funding through the purchase of shares of the Company’s common stock. During the term of the agreement, the Company may deliver a put notice to Tangiers, which will specify the number of shares which the Company will sell to Tangiers. The maximum amount that the Company shall be entitled to put to Tangiers per any applicable put notice is that number of shares of our common stock up to or equal to 400% of the average of the daily trading volume of our common stock for the eight consecutive trading days immediately prior to the date of the applicable put notice. The minimum amount the Company can draw down at any one time is $5,000, and the maximum amount the Company can draw down at any one time is $1,000,000, as determined by multiplying the put amount by the average daily volume weighted average prices of our common stock for the ten (10) trading days immediately prior to the applicable put notice. A closing will occur on the date which is no earlier than five (5) trading days following, and no later than seven (7) trading days following, the applicable put notice. On each closing date, the Company will sell, and Tangiers will purchase, the shares of the Company’s common stock specified in the put notice. The amount to be paid by Tangiers on a particular closing date will be determined by multiplying the purchase price by the number of shares specified in the put notice. The purchase price is 85% of the average the two lowest volume weighted average trading prices of the Company’s common stock during the pricing period applicable to the put notice. The pricing period, with respect to a particular put notice, is five consecutive trading days including, and immediately following, the delivery of a put notice to Tangiers. The Company may submit a put notice once every eight trading days, provided the closing of the previous transaction has taken place. The Company is under no obligation to submit any put notices. The Company has filed a Registration Statement with the Securities and Exchange Commission so that the shares of common stock to be sold to Tangiers may be sold in the public market. The equity line agreement will become effective on the date the Registration Statement is declared effective by the Securities and Exchange Commission. Clinical Trial Agreement Under the terms of an agreement dated November 11, 2017, we committed to cover the costs to perform clinical trials with The University of the West Indies through the Topical Metabolism Research Unit of the Caribbean Institute for Health Research located in Kingston, Jamaica, initially scheduled as follows: · An instalment of $50,000 upon both the approval of specific protocol by the Ethics Committee of the Institutional Review Board of the Ministry of Health, Jamaica, and the execution of the clinical trial agreement, · An instalment of $51,182 upon the enrollment of the 12 th · An instalment of $51,182 after all twelve patients go through the washout period determined in the specific protocol and return for a second dose, and · An instalment of $51,182 upon completion of the clinical trial. Additionally, we have agreed to reimburse The University of the West Indies for care and treatment of adverse reactions or injury sustained by a patient, as a direct result of the clinical trial. Research Laboratory Under the terms of a research agreement entered into in October 2017 with the University of Florida Trustees (“UFT”), we committed to pay UFT $151,772, upon the execution of the research agreement, and $75,886 in each of the months of February 2018 and June 2018, for a total commitment of $303,544. Executive Office Lease Effective August 1, 2018, we signed a thirty-six-month lease of approximately 6,683 square feet of commercial office space in Golden, Colorado that we use as our executive offices. The lease expires on July 31, 2020 and requires the payment of monthly base rental rates of $3,302 through July 31, 2018, $3,000 through July 31, 2019 and $3,799 through July 31, 2020. As additional rent, we are required to pay for an allocation of common area costs and expenses, plus all utilities. Weldona Facility Lease Effective October 1, 2017, we entered into a lease of approximately 40,000 square feet of industrial space in Weldona, Colorado that we us as our hemp extraction facility and hemp cultivation center. The term of the lease expires on October 31, 2018, with an annual option to renew that expires on September 30, 2022. The rent is $7,500 per month throughout the term of the lease, plus we are responsible for all utilities. Legal Proceedings There have been no material developments in legal proceedings in which we are involved as of March 31, 2018.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 17 – SUBSEQUENT EVENTS On April 2, 2018, we entered into a 5%, unsecured promissory note (“Note”) in the principal amount of $600,000 that is due six months from the date of the loan. Proceeds from under the terms of the Note in the amount $570,000 were used by the Company to acquire additional equipment for our new extraction facility and for working capital purposes In accordance with ASC 855-10 we have analyzed the Company’s operations subsequent to March 31, 2018 to the date these consolidated financial statements were issued, and have determined that, other than as disclosed above, we do not have any material subsequent events to disclose in these consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN23

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
Use of Estimates	Use of Estimates We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Level 1 Level 2 Level 3 The carrying amount of our cash and cash equivalents, accounts receivable, accounts payable, and other current assets and liabilities in our consolidated financial statements approximates fair value because of the short-term nature of the instruments. Investments in non-marketable equity securities are carried at cost less other-than-temporary impairments. The carrying amount of our notes payable and convertible debt at March 31, 2018, approximates their fair values based on our incremental borrowing rates. There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the three-month period ended March 31, 2018 and the year ended December 31, 2017.
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable, Net	Accounts Receivable, Net
Prepaid Expenses	Prepaid Expenses -
Inventory	Inventory –
Property and Equipment	Property and Equipment March 31, December 31, 2018 2017 Construction in process - extraction facilities Weldona, Colorado extraction facility: Equipment $ — $ 647,947 Jamaica cultivation and extraction facility: Leasehold improvements - laboratory — 75,000 Leasehold improvements - cultivation 110,699 109,750 $ 110,699 $ 832,697 Extraction facility and laboratory equipment, and office furniture and fixtures Equipment and machinery at Weldona extraction facility $ 1,154,909 — Golden, Colorado hemp laboratory - equipment 39,944 34,651 Golden, Colorado administrative offices: Furniture and fixtures 46,849 21,668 Leasehold improvements 2,000 2,000 Transportation equipment 81,667 81,667 Remote laboratory equipment 99,220 99,220 1,424,589 239,206 Accumulated amortization and depreciation (91,524 ) (39,385 ) $ 1,333,065 $ 199,821
Granted Patents	Granted Patents –
Intangible Assets	Intangible Assets –
Long-Lived Assets Impairment Assessment	Long-Lived Assets Impairment Assessment We have not recorded any impairment charges related to long-lived assets as of March 31, 2018 or December 31, 2017.
Equity Method Investments	Equity Method Investments
Goodwill	Goodwill
Purchase Price Allocation	Purchase Price Allocation Business Combinations Fair Value Measurements and Disclosures
Deferred Revenue	Deferred Revenue
Revenue Recognition	Revenue Recognition - Revenue from Contracts with Customers over time Revenue for services with a payment in the form of stock, warrants or other financial assets is recognized when the services are performed. The value of revenue paid for with warrants is measured using the Black-Scholes-Merton pricing model. Revenue from product sales, including delivery fees, is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. Reimbursable expenses, including those relating to travel, other out-of-pocket expenses and any third-party costs, are included as a component of revenues. Typically, an equivalent amount of reimbursable expenses is included in cost of revenues. Reimbursable expenses related to time and materials and fixed-fee engagements are recognized as revenue in the period in which the expense is incurred and collectability is reasonably assured. Taxes collected from customers and remitted to governmental authorities are presented in our consolidated statement of operations on a net basis. Revenue Recognition – Affiliate Prana Prana Prana Prana Prana Prana Revenue from Contracts with Customers.
Cost of Revenues	Cost of Revenues
Research and Development Expenses	Research and Development Expenses -
General and Administrative Expenses	General and Administrative Expenses -
Stock-Based Compensation	Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation
Income Taxes	Income Taxes We follow the provisions of ASC 740, Income Taxes When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations. On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no impact on our income taxes for the year ended year-ended December 31, 2017.
Commitments and Contingencies	Commitments and Contingencies - Certain conditions may exist as of the date our consolidated financial statements are issued, which may result in a loss but which will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.
Net Loss Per Share	Net Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Three Months Ended March 31, 2018 2017 Warrants to purchase common stock 1,234,027 1,541,112 Stock options, exercisable 11,705,000 3,680,000 Total potentially dilutive securities 12,939,027 5,221,112
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss)
Segment Reporting	Segment Reporting –
Concentration of Credit Risk	Concentration of Credit Risk The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Three Months Ended March 31, 2018 2017 Customer A 62% 98% Customer B 21% 2% Customer C 17% —% Percentage of Accounts Receivable: As of March 31, 2018 2017 Customer C 100% 93% Customer D —% 7% Customer E —% —%
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued guidance on leases which requires entities to recognize right-of-use assets and lease liabilities on the balance sheet for the rights and obligations created by all leases, including operating leases, with terms of more than 12 months. The new guidance also requires additional disclosures on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The new guidance will be effective for us at the beginning of fiscal year 2019. Early adoption is permitted. We are in the process of evaluating the impact the adoption of this guidance will have on our consolidated financial statements and related disclosures.
Reclassification	Reclassification -

SUMMARY OF SIGNIFICANT ACCOUN24

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Schedule of Property and Equipment	March 31, December 31, 2018 2017 Construction in process - extraction facilities Weldona, Colorado extraction facility: Equipment $ — $ 647,947 Jamaica cultivation and extraction facility: Leasehold improvements - laboratory — 75,000 Leasehold improvements - cultivation 110,699 109,750 $ 110,699 $ 832,697 Extraction facility and laboratory equipment, and office furniture and fixtures Equipment and machinery at Weldona extraction facility $ 1,154,909 — Golden, Colorado hemp laboratory - equipment 39,944 34,651 Golden, Colorado administrative offices: Furniture and fixtures 46,849 21,668 Leasehold improvements 2,000 2,000 Transportation equipment 81,667 81,667 Remote laboratory equipment 99,220 99,220 1,424,589 239,206 Accumulated amortization and depreciation (91,524 ) (39,385 ) $ 1,333,065 $ 199,821
Schedule of potentially dilutive securities that have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive	Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Three Months Ended March 31, 2018 2017 Warrants to purchase common stock 1,234,027 1,541,112 Stock options, exercisable 11,705,000 3,680,000 Total potentially dilutive securities 12,939,027 5,221,112
Schedule of significant concentrations in revenues and accounts receivable	The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Three Months Ended March 31, 2018 2017 Customer A 62% 98% Customer B 21% 2% Customer C 17% —% Percentage of Accounts Receivable: As of March 31, 2018 2017 Customer C 100% 93% Customer D —% 7% Customer E —% —%

OPERATING LEASES (Tables)

OPERATING LEASES (Tables)	3 Months Ended
	Mar. 31, 2018
Leases [Abstract]
Schedule of Operating Leases	Future minimum payments for these leases are: For the twelve Months Ending March 31, 2019 2020 2021 2021 2022 $131,208 $134,398 $105,198 $90,001 $45,001

INVENTORY (Tables)

INVENTORY (Tables)	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	We periodically review the value of our inventory and provide a write-down of inventory based on our assessment of the market conditions. Any write-down is charged to cost of goods sold. At ended March 31, 2018 and December 31, 2017, our inventory is, as follows: March 31, December 31, 2018 2017 Raw materials $ 38,376 $ 15,000 Work-in-process 57,565 — Finished goods 41,200 28,200 $ 137,141 $ 43,200

PURCHASE OF PRANA THERAPUETIC27

PURCHASE OF PRANA THERAPUETICS, INC. (Tables)	3 Months Ended
	Mar. 31, 2018
Business Combinations [Abstract]
Schedule of allocation of purchase price	The purchase price for Prana was allocated to the net tangible and intangible assets based upon their fair values as of the acquisition date. The excess of the purchase price over the fair values of the net tangible assets and intangible assets was recorded as goodwill and is generally driven by management’s expectations and ability to realize synergies and achieve strategic growth. The allocation of the purchase price was, as follows: March 31, Patents $ 52,596 Net assets 522,761 Goodwill 4,495,143 Total $ 5,070,500

DEFERRED REVENUE (Tables)

DEFERRED REVENUE (Tables)	3 Months Ended
	Mar. 31, 2018
Deferred Revenue Disclosure [Abstract]
Schedule of deferred revenue	Our deferred revenue consists of: March 31, December 31, 2018 2017 Deferred revenue – WeedMD $ 158,750 $ 203,750 Less – current portion (158,750 ) (180,000 ) Deferred revenue, net of current portion $ — $ 23,750

NOTES PAYABLE TO AND ADVANCES29

NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS (Tables) (USD $)	3 Months Ended
	Mar. 31, 2018
Notes Payable To And Advances From Officers And Directors Tables Usd
Notes payable to and advance from officers and directors	Notes payable to and advance from officers and directors consisted of the following: March 31, December 31, 2018 2017 Note payable to Earnie Blackmon, an officer and director $ 332,760 $ 246,458 Note payable to Tony Verzura, an officer and director 15,844 14,889 $ 348,604 $ 261,347

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2018
Summary of stock options outstanding	The following table summarizes our stock options outstanding as of both March 31, 2018 and December 31, 2017, respectively: Number of Weighted Weighted Stock options outstanding at January 1, 2017 3,680,000 8.9 $ 0.28 Issued 3,957,500 Exercised (1,000,000 ) Expired — Stock options outstanding at December 31, 2017 6,637,500 8.7 $ 0.57 Stock options exercisable at December 31. 2017 6,580,000 8.7 0.57 Stock options outstanding at December 31, 2017 6,637,500 Issued 6,000,000 9.9 1.08 Exercised — Expired — Stock options outstanding at March 31, 2017 12,637,500 9.2 0.78 Stock options exercisable at March 31, 2018 11,705,000 9.2 $ 0.78
Stock Options [Member]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value	We calculated the fair value of each option to be approximately $0.91 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 1.05 Exercise price $ 1.08 Risk free interest rate 2.8 % Expected term (years) 5-10 Expected volatility 197 % Expected dividends 0 %
Warrants [Member]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value	Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 %
Summary of share warrants outstanding	The following table summarizes our share warrants outstanding as of March 31, 2018 and December 31, 2017: March 31, December 31, 2018 2017 Number of Shares Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price Warrants outstanding, beginning of period 1,209,025 $ 0.21 $ 1,551,356 $ 0.18 Warrants issued to consultants 25,002 132,669 Warrants exercised — (475,000 ) Warrants outstanding, end of period 1,234,027 $ 0.27 1,209,025 $ 0.21 Warrants exercisable, end of period 1,234,027 $ 0.27 1,209,025 $ 0.21

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of share-based compensation expense	Share-based compensation expense for the three months ended Mach 31, 2018 and 2017 is, as follows: Three Months Ended March 31 2018 2017 Warrants issued for consulting and other services $ — $ 91,333 Common stock issued for accounts payable and accrued expenses — 43,376 Common stock issued for services 65,885 120,616 Common stock issued for advisory board fees 56,043 — Common stock issued as compensation to employees 42,300 — Stock options issued to officers and directors 5,324,754 — $ 5,488,982 $ 255,325

BUSINESS ORGANIZATION AND NAT32

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS (Details) - USD ($)	Jul. 14, 2017	Mar. 31, 2014	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Mar. 26, 2014
Amount of payable owed to former officer and director, exchanged for assets sold		$ 15,000
Number of common shares issued in exchange for certain intellectual property		38,690,000
Total number of common shares previously outstanding, cancelled during period						41,690,000
Common stock, shares outstanding			64,229,926	62,862,066		43,620,000
Prana [Member]
Common shares received in exchange for future consulting services and use of our intellectual property	5,730,000
Fair market value of common stock	$ 5,070,500
Closing price per share	$ 0.85
Prana [Member] | Subscription Agreement [Member]
Shares of investment owned	400,000
Investments in non-marketable equity securities	$ 200,000		$ 50,000	$ 50,000	$ 50,000

SUMMARY OF SIGNIFICANT ACCOUN33

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	3 Months Ended
	Mar. 31, 2018USD ($)Item	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)
Property, Plant and Equipment [Line Items]
Number of operating segment | Item	1
Allowance for doubtful accounts	$ 0		$ 0
Bad debt expense, included in general and administrative expenses	0	$ 0
Goodwill	4,838,603		$ 4,838,603
Purchase Price Allocation	5,070,500
Excess of purchase price over fair values of net tangible assets and intangible assets recorded as goodwill	$ 4,731,729
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Estimated useful life	10 years
Equity Method Investments, Percentage	50.00%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Estimated useful life	15 years
Equity Method Investments, Percentage	20.00%
Patents [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years
PTI [Member]
Property, Plant and Equipment [Line Items]
Equity Method Investments, Percentage	95.00%
Goodwill	$ 4,495,143
Purchase Price Allocation	$ 5,070,500
CRD [Member]
Property, Plant and Equipment [Line Items]
Equity Method Investments, Percentage	50.00%
Goodwill	$ 106,873

SUMMARY OF SIGNIFICANT ACCOUN34

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment) (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Construction in process - extraction facilities	$ 110,699	$ 832,697
Extraction facility and laboratory equipment, and office furniture and fixtures	1,424,589	239,206
Accumulated amortization and depreciation	(91,524)	(39,385)
Cultivation facility and laboratory equipment and Office furniture and fixtures	1,333,065	199,821
Equipment [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Construction in process - extraction facilities		647,947
Leasehold Improvements [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility and laboratory equipment, and office furniture and fixtures	2,000	2,000
Leasehold Improvements - Cultivation [Member] | Jamaica Cultivation and Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Construction in process - extraction facilities	110,699	109,750
Leasehold Improvements - Laboratory [Member] | Jamaica Cultivation and Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Construction in process - extraction facilities		75,000
Golden, Colorado Hemp Laboratory - Equipment [Member]
Property, Plant and Equipment [Line Items]
Extraction facility and laboratory equipment, and office furniture and fixtures	39,944	34,651
Furniture and Fixtures [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility and laboratory equipment, and office furniture and fixtures	46,849	21,668
Transportation Equipment [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility and laboratory equipment, and office furniture and fixtures	81,667	81,667
Remote Laboratory Equipment [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility and laboratory equipment, and office furniture and fixtures	99,220	99,220
Equipment and machinery at Weldona extraction facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility and laboratory equipment, and office furniture and fixtures	$ 1,154,909

SUMMARY OF SIGNIFICANT ACCOUN35

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of anti-dilutive securities) (Details) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	12,939,027	5,221,112
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	1,234,027	1,541,112
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	11,705,000	3,680,000

SUMMARY OF SIGNIFICANT ACCOUN36

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of concentration of credit risk) (Details)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	62.00%	98.00%
Revenue [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk percentage	21.00%	2.00%
Revenue [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	17.00%
Accounts Receivable [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100.00%	93.00%
Accounts Receivable [Member] | Customer D [Member]
Concentration Risk [Line Items]
Concentration risk percentage		7.00%
Accounts Receivable [Member] | Customer E [Member]
Concentration Risk [Line Items]
Concentration risk percentage

GOING CONCERN (Details)

GOING CONCERN (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
GOING CONCERN [Abstract]
Net loss	$ 7,206,560	$ 815,976
Net cash used in operating activities	1,651,026	$ 109,800
Working capital deficit	511,153
Accumulated deficit	$ 22,476,406		$ 15,269,845

RECEIVABLE FROM RELATED PARTY (

RECEIVABLE FROM RELATED PARTY (Schedule of Amounts Due from Related Parties) (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Due from related parties	$ 14,961
Advesa [Member]
Related Party Transaction [Line Items]
Due from related parties	$ 14,861	$ 0

OPERATING LEASES (Narrative) (D

OPERATING LEASES (Narrative) (Details)	Oct. 01, 2017ft²	Aug. 01, 2017ft²	Mar. 31, 2018USD ($)a	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
CRD [Member]
Operating Leased Assets [Line Items]
Equity Method Investments, Percentage			50.00%
Lease amount from father of directors and members			$ 1
Hemp Laboratory - Golden, Colorado [Member]
Operating Leased Assets [Line Items]
Area of lease | ft²		9,882
Maturity date		Jul. 31, 2020
Hemp Laboratory - Golden, Colorado [Member] | Subsequent Event [Member]
Operating Leased Assets [Line Items]
Basic rent per month				$ 3,800	$ 3,500	$ 3,302
Colorado Extraction Facility [Member]
Operating Leased Assets [Line Items]
Area of lease | ft²	40,000
Maturity date	Sep. 30, 2018
Basic rent per month			$ 7,500
Jamaica Cultivation and Extraction Facility [Member]
Operating Leased Assets [Line Items]
Area of lease | a			28

OPERATING LEASES (Schedule of F

OPERATING LEASES (Schedule of Future Minimum Payament) (Details)	Mar. 31, 2018USD ($)
Leases [Abstract]
2,019	$ 131,208
2,020	134,398
2,021	105,198
2,021	90,001
2,022	$ 45,001

INVENTORY (Details)

INVENTORY (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 38,376	$ 15,000
Work-in-process	57,565
Finished goods	41,200	28,200
Inventory	$ 137,141	$ 43,200

PURCHASE OF PRANA THERAPUETIC42

PURCHASE OF PRANA THERAPUETICS, INC. (Narrative) (Details) - Prana [Member] - USD ($)	Jul. 14, 2017	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017
Business Acquisition [Line Items]
Common shares received in exchange for future consulting services and use of our intellectual property	5,730,000
Fair market value of common stock	$ 5,070,500
Closing price per share	$ 0.85
Shares issued in acquisition	400,000
Shares issued in acquisition, value	$ 200,000
Subscription Agreement [Member]
Business Acquisition [Line Items]
Shares of investment owned	400,000
Investments in non-marketable equity securities	$ 200,000	$ 50,000	$ 50,000	$ 50,000

PURCHASE OF PRANA THERAPUETIC43

PURCHASE OF PRANA THERAPUETICS, INC. (Schedule of Purchase Price Allocation) (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	$ 4,838,603	$ 4,838,603
Purchase Price Allocation	5,070,500
PTI [Member]
Business Acquisition [Line Items]
Patents	52,596
Net assets	522,761
Goodwill	4,495,143
Purchase Price Allocation	$ 5,070,500

GRANTED PATENT (Details)

GRANTED PATENT (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Aug. 15, 2017
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	$ 4,458		$ 2,679
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful live	15 years
Amortization expense	$ 4,458	$ 0
Accumulated amortization	$ 4,458		$ 2,679
Research, legal fees				$ 142,317

INTANGIBLES (Details)

INTANGIBLES (Details)	3 Months Ended
	Mar. 31, 2018
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	15 years
Design Marks and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	10 years

INSTALLMENT LOAN PAYABLE (Detai

INSTALLMENT LOAN PAYABLE (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Installment Loan Payable Details
Installment loan payable	$ 32,757	$ 46,667
Installment loan monthly payment	955
Monthly payments being made to pay off loan in six months	$ 6,955

DEFERRED REVENUE (Narrative) (D

DEFERRED REVENUE (Narrative) (Details) - WeedMD RX Inc. (''WMD'') [Member] - USD ($)	Jun. 09, 2014	Mar. 31, 2018	Dec. 31, 2014	Sep. 30, 2016	Dec. 31, 2017
Deferred Revenue Arrangement [Line Items]
Common shares received in exchange for future consulting services and use of our intellectual property	1,187,500
Warrants received in exchange for future consulting services and use of our intellectual property	3,000,000
Fair value of securities recorded as deferred revenue	$ 893,750
Deferred revenue recognized per month		$ 15,000
Total deferred revenue recognized		$ 45,000	$ 150,000	$ 158,750	$ 180,000

DEFERRED REVENUE (Schedule of d

DEFERRED REVENUE (Schedule of deferred revenue) (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Deferred Revenue Arrangement [Line Items]
Less - current portion	$ 158,750	$ 180,000
Deferred revenue, net of current portion		23,750
WeedMD RX Inc. (''WMD'') [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 158,750	$ 203,750

CONVERTIBLE NOTE PAYABLE (Narra

CONVERTIBLE NOTE PAYABLE (Narrative) (Details) - Convertible Notes Payable [Member] - USD ($)	Aug. 10, 2016	Oct. 16, 2016
Debt Instrument [Line Items]
Debt instrument, interest rate	12.00%
Percentage of principal amount increase if company paid anytime	25.00%	25.00%
Expiration date	May 10, 2017
Proceeds from debt, net	$ 125,000
Average closing price of common stock	$ 0.20
Conversions rate on issue and outstandng common stock	4.99%
Thereafter October 16, 2016 [Member]
Debt Instrument [Line Items]
Percentage of principal amount increase if company paid anytime		30.00%

NOTES PAYABLE TO AND ADVANCES50

NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Dec. 30, 2016	Apr. 06, 2016	Oct. 12, 2015
Related Party Transaction [Line Items]
Principal balance increase			$ 57,500
Debt repayment terms	If the loans are repaid on or before September 30, 2016, the principal amount, which is being repaid, will increase by 10%. If the loans are repaid after September 30, 2016, the principal amount, which is being repaid will increase by 15%.
Earnie Blackmon [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	$ 332,760	$ 246,458
Tony Verzura [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount				$ 25,000
Tony Verzura [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	15,844	14,889
Accrued wages payable to officers and directors [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	$ 348,604	$ 261,347
Ernest Blackmon [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount				$ 25,000
JSJ Investments Inc. [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party					$ 102,000
JSJ Investments Inc. [Member]
Related Party Transaction [Line Items]
Debt instrument, interest rate			12.00%

STOCKHOLDERS' EQUITY (Narrative

STOCKHOLDERS' EQUITY (Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Jul. 18, 2017	Mar. 31, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Aggregate intrinsic value of warrants outstanding and exercisable		$ 0
Warrant issued		25,002	132,669
Warrants [Member]
Class of Stock [Line Items]
Warrant issued			666,667
Weighted-average remaining contractual life for stock options outstanding and exercisable		3 years 7 months 6 days
Preferred Class A [Member] | Officer and Director [Member]
Class of Stock [Line Items]
Share issued	2,000
Proceeds from shares issued	$ 2,200

STOCKHOLDERS' EQUITY (Common St

STOCKHOLDERS' EQUITY (Common Stock Issued For Services, Warrants) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Number of Shares
Warrants outstanding, beginning of period	1,209,025	1,551,356
Warrants issued to consultants	25,002	132,669
Warrants exercised		(475,000)
Warrants outstanding, end of period	1,234,027	1,209,025
Warrants exercisable, end of period	1,234,027	1,209,025
Weighted Average Exercise Price
Warrants outstanding, beginning of period (in dollars per share)	$ 0.21	$ 0.18
Warrants outstanding, end of period (in dollars per share)	0.27	0.21
Warrants exercisable, end of period (in dollars per share)	$ 0.27	$ 0.21

STOCKHOLDERS' EQUITY (Schedule

STOCKHOLDERS' EQUITY (Schedule of Assumptions on Date of Valuation Utilizing for Fair Value of Warrants) (Details) - $ / shares	1 Months Ended	3 Months Ended
	Feb. 28, 2018	Mar. 31, 2018
Warrants [Member]
Class of Stock [Line Items]
Exercise price (in dollars per share)		$ 0.18
Expected term (years)		5 years
Expected dividends (as a percent)		0.00%
Warrants [Member] | Minimum [Member]
Class of Stock [Line Items]
Stock price (in dollars per share)		$ 0.16
Risk free interest rate (as a percent)		1.01%
Expected volatility (as a percent)		322.00%
Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Stock price (in dollars per share)		$ 2.18
Risk free interest rate (as a percent)		1.37%
Expected volatility (as a percent)		504.00%
Stock Options [Member]
Class of Stock [Line Items]
Stock price (in dollars per share)	$ 1.05
Exercise price (in dollars per share)	$ 1.08
Risk free interest rate (as a percent)	2.80%
Expected volatility (as a percent)	197.00%
Expected dividends (as a percent)	0.00%
Stock Options [Member] | Minimum [Member]
Class of Stock [Line Items]
Expected term (years)	5 years
Stock Options [Member] | Maximum [Member]
Class of Stock [Line Items]
Expected term (years)	10 years

STOCKHOLDERS' EQUITY (Schedul54

STOCKHOLDERS' EQUITY (Schedule of stock option activity) (Details) - Stock Options [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Stock options outstanding, beginning of period	6,637,500	3,680,000	600,000
Issued	6,000,000	3,957,500
Exercised		(1,000,000)
Expired
Stock options outstanding, end of period	12,637,500	6,637,500	3,680,000
Stock options outstanding, end of period	11,705,000	6,580,000
Weighted Average Exercise Price
Stock options outstanding, beginning of period	$ 0.57	$ 0.28	$ 0.70
Issued	1.08
Stock options outstanding, end of period	0.78	0.57	$ 0.28
Stock options exercisable, end of period	$ 0.78	$ 0.57
Weighted Average Remaining Life (Years)
Stock options outstanding, beginning of period	9 years 2 months 12 days	8 years 8 months 12 days	8 years 10 months 25 days
Stock options Issued, end of period	9 years 10 months 25 days
Stock options exercisable, end of period	9 years 2 months 12 days	8 years 8 months 12 days

STOCKHOLDERS' EQUITY (Stock Opt

STOCKHOLDERS' EQUITY (Stock Option Activity) (Narrative) (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Feb. 28, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options compensation	$ 5,324,754
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of options	6,146,000
Weighted-average remaining contractual life for stock options outstanding and exercisable	9 years 2 months 12 days		8 years 8 months 12 days
Aggregate intrinsic value of options outstanding and exercisable	$ 1
Option vested	5,125,000
Stock options compensation	$ 5,324,754
Stock Options [Member] | Vesting through December 31, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vested	875,000
2017 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awarded stock options				$ 6,000,000

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Warrants issued for consulting and other services		$ 91,333
Common stock issued for accounts payable and accrued expenses		43,376
Common stock issued for services	65,885	120,616
Common stock issued for advisory board fees	56,043
Common stock issued as compensation to employees	42,300
Stock options issued to officers and directors	5,324,754
Share-based compensation	$ 5,488,982	$ 255,325

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2018USD ($)ft²	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jan. 19, 2018USD ($)	Oct. 31, 2017USD ($)
Other Commitments [Line Items]
Minimum amount draw down at one time	$ 5,000
Percentage of number of common shares	400.00%
Maximum amount draw down at one time	$ 1,000,000
Percentage of trading price	85.00%
Executive Office Lease [Member]
Other Commitments [Line Items]
Lease term	36 months
Lease space | ft²	6,683
Lease expiration date	Jul. 31, 2020
Monthly rental rates	$ 3,302
Executive Office Lease [Member] | Subsequent Event [Member]
Other Commitments [Line Items]
Monthly rental rates		$ 3,799	$ 3,000
Weldona Facility Lease [Member]
Other Commitments [Line Items]
Lease space | ft²	40,000
Lease expiration date	Sep. 30, 2022
Monthly rental rates	$ 7,500
Prana [Member]
Other Commitments [Line Items]
Total commitment upon execution of research agreement					$ 151,772
Commitment owed in February 2018					75,886
Commitment owed in June 2018					75,886
Total commitment amount owed					$ 303,544
Tangiers Global, LLC [Member]
Other Commitments [Line Items]
Line of Credit agreement				$ 10,000,000
Clinical Trial Agreement [Member] | Installment One [Member]
Other Commitments [Line Items]
Payment made for clinical trial agreement	50,000
Clinical Trial Agreement [Member] | Installment Two [Member]
Other Commitments [Line Items]
Payment made for clinical trial agreement	51,182
Clinical Trial Agreement [Member] | Installment Three [Member]
Other Commitments [Line Items]
Payment made for clinical trial agreement	51,182
Clinical Trial Agreement [Member] | Installment Four [Member]
Other Commitments [Line Items]
Payment made for clinical trial agreement	$ 51,182

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - Unsecured Promissory Note [Member]	1 Months Ended
	Apr. 30, 2018USD ($)
Subsequent Event [Line Items]
Debt instrument face amount	$ 600,000
Debt interest rate	5.00%
Proceeds from debt	$ 570,000